HALOBETASOL PROPIONATE; TAZAROTENE
| Brand name | DUOBRII |
|---|---|
| Active ingredient | HALOBETASOL PROPIONATE; TAZAROTENE |
| Strength | 0.01%;0.045% |
| Dosage form | LOTION |
| Route | TOPICAL |
| Modality | Small molecule |
| FDA approval | April 2019 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11679115 | June 2036 | product |
| 10251895 | June 2036 | product |
| 10426787 | June 2036 | use U-2625 |
| 11648256 | June 2036 | product |
| 8809307 | November 2031 | product |
| 10478502 | November 2031 | product |
| 11957753 | November 2031 | product |
| 11839656 | November 2031 | use U-2625 |
| 11986527 | November 2031 | use U-2625 |
| 12076403 | November 2031 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.